2764.6000 -73.80 (-2.60%)
NSE Jan 09, 2026 15:31 PM
Volume: 164.6K
 

logo
Ajanta Pharma Ltd.
10 Aug 2017
2764.60
-2.60%
ICICI Securities Limited
Revenues remained flat YoY at | 473 crore (I-direct estimate: | 486 crore). Domestic growth was impacted by GST transition while export formulation growth was driven by robust growth in the US EBITDA margins declined 802 bps YoY to 26.8% (I-direct estimate: 31%) mainly due to the impact of GST transition and higher fixed overheads due to commissioning of new plants Adjusted net profit declined 21% YoY to | 95 crore (I-direct estimates: | 100 crore). Lower tax rate (20% against 24% in Q1FY17)...
Promoters pledged 1.16% of shares in last quarter. Total pledge stands at 15.28% of promoter holdings
More from Ajanta Pharma Ltd.
Recommended